EQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and biotech venture capital firm Claris Ventures (“Claris”) today announced an acceleration framework to streamline programmes from Claris’s portfolio companies into the clinic through Evotec’s fully integrated platform.
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic 06.03.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement.
Hamburg, Germany, and Turin, Italy, 06 March 2024:
06.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | [email protected] |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1851857 |
End of News | EQS News Service |
|
1851857 06.03.2024 CET/CEST